Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma

Inclusion criteria

• ✓. The subject has voluntarily signed the informed consent form with full consent, and is willing and able to comply with the scheduled visits, study treatments, laboratory tests, and other trial procedures
• ✓. Patients with relapsed/refractory B-cell lymphoma confirmed by cytology or histology according to the WHO 2022 Classification:
• ✓. Aged 18-75 years (inclusive), male or female
• ✓. Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
• ✓. Estimated overall survival of more than 3 months from the date of signing the informed consent form
• ✓. Hemoglobin (HGB) ≥ 70 g/L (transfusion permitted)
• ✓. Adequate hepatic, renal and cardiopulmonary function meeting the following criteria:
• ✓. The subject agrees to use contraceptive measures from the date of signing the informed consent form until 1 year after CAR-T cell infusion